The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 30, 2024

Filed:

May. 11, 2020
Applicant:

Novartis Ag, Basel, CH;

Inventors:

Huixiang Zhang, Fort Worth, TX (US);

Charles Boring, Fort Worth, TX (US);

Alok Kulshreshtha, Grapevine, TX (US);

Yuhong Zeng, Fort Worth, TX (US);

Li Wan, Fort Worth, TX (US);

Laman Alani, Fort Worth, TX (US);

Assignee:

NOVARTIS AG, Basel, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61B 3/12 (2006.01); A61B 5/00 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01); C07K 16/22 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/22 (2013.01); A61B 3/12 (2013.01); A61B 5/4848 (2013.01); A61K 9/0048 (2013.01); A61K 39/3955 (2013.01); A61K 39/39591 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.


Find Patent Forward Citations

Loading…